NASDAQ · Biotechnology

ALT (ALT) Stock

$3.03 -1.30% NASDAQ: ALT Healthcare

Valuation

MetricValue
Price$3.03
Market Cap$267.42M
P/E Ratio-2.31
P/B Ratio1.50
P/S Ratio7268.97
EPS (TTM)$-1.32
52-Week High$7.73
52-Week Low$2.56
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-50.57%
ROA-28.17%
ROCE-41.78%
Gross Margin—
Operating Margin—
Net Margin-2530.03%
Debt/Equity0.13
Current Ratio18.53

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.0M$0$0$0$0
Operating Profit$-97.0M$-88.0M$-96.0M$-103.0M$-94.0M
Net Profit$-97.0M$-85.0M$-88.0M$-95.0M$-88.0M
EPS$-2.35$-1.81$-1.66$-1.34$-1.00
Op Margin-2197.6%129029.4%-22518.5%-515860.0%-230461.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$219.0M$207.0M$211.0M$139.0M$280.0M
Total Liabilities$20.0M$22.0M$17.0M$16.0M$55.0M
Cash$190.0M$111.0M$135.0M$37.0M$44.0M
Borrowings$2.0M$1.0M$1.0M$2.0M$36.0M

Latest News

US Research house initiates Solvonis coverage citing differentiated addiction strategy Proactive · Jul 13, 2026 Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market Insider Monkey · Jul 5, 2026 Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker Zacks · Jun 26, 2026 5 Small Drug Stocks to Invest in Amid a Biotech Comeback Zacks · Jun 25, 2026 Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20? Insider Monkey · Jun 24, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-78.0M$-63.0M$-76.0M$-80.0M$-68.0M
Investing Cash Flow$75.0M$-74.0M$14.0M$-28.0M$-132.0M
Financing Cash Flow$0$0$0$0$-1.0M
Net Cash Flow$74.0M$-79.0M$24.0M$-98.0M$7.0M
Free Cash Flow$-91.0M$-63.0M$-76.0M$-80.0M$-68.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-31.52
EV / EBITDA—
FCF Yield-27.50%
Quick Ratio29.56
Interest Coverage-47.00
Return 1Y-33.80%
Return 3Y-8.09%
Return 5Y-66.01%

Ownership

Insiders Held0.41%
Institutions Held58.06%
Institutions Float Held58.30%
Institutional HolderSharesReport Date
Blackrock Inc.12,795,2772026-03-31
State Street Corporation7,145,5502026-03-31
Vanguard Capital Management LLC5,658,0492026-03-31
Vanguard Portfolio Management LLC5,382,0022026-03-31
Marshall Wace LLP4,017,9012026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIU $2.31 +0.22% -4.04 $234.59M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
ANNX $5.37 +0.75% -3.71 $879.83M 0.00%
ANRO $28.67 +0.70% -6.29 $1.01B 0.00%
AURA $7.06 -1.40% -4.35 $453.25M 0.00%

About ALT

ALT is led by CEO Jerome Benedict Durso, employs 59 people, headquartered in US, publicly traded since 2017.

ALT stock trades at $3.03 with a market capitalization of $267.42M. The stock is valued at a price-to-earnings (P/E) ratio of -2.31, price-to-book of 1.50, price-to-sales of 7268.97. Over the past 52 weeks the stock has ranged between $2.56 and $7.73, and currently trades 60.8% below its 52-week high.

On profitability, ALT generates a return on equity (ROE) of -50.57%, return on capital employed of -41.78%, a net profit margin of -2530.03%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides